IP Verse

Anti-Ifnar1 Dosing Regime For Subcutaneous Injection - EP4114465

The patent EP4114465 was granted to Astrazeneca on Aug 30, 2023. The application was originally filed on Apr 21, 2022 under application number EP22724683A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP4114465

ASTRAZENECA
Application Number
EP22724683A
Filing Date
Apr 21, 2022
Status
Granted And Under Opposition
Jul 28, 2023
Grant Date
Aug 30, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MAIWALDMay 29, 2024MAIWALDADMISSIBLE

Patent Citations (22) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONCN113278070
DESCRIPTIONUS10125195
DESCRIPTIONUS7662381
DESCRIPTIONUS7741449
DESCRIPTIONUS9493570
DESCRIPTIONUS9988459
DESCRIPTIONWO2009011770
DESCRIPTIONWO2011028933
DESCRIPTIONWO2013188494
DESCRIPTIONWO2018023976
INTERNATIONAL-SEARCH-REPORTCN113521276B
INTERNATIONAL-SEARCH-REPORTUS2006029601
INTERNATIONAL-SEARCH-REPORTUS2017051066
INTERNATIONAL-SEARCH-REPORTUS2020399381
INTERNATIONAL-SEARCH-REPORTWO2022074123
INTERNATIONAL-SEARCH-REPORTWO2022106460
OPPOSITIONEP3769781
OPPOSITIONWO2021094378
OPPOSITIONWO2021239928
OPPOSITIONWO2022074123
OPPOSITIONWO2022106460
OPPOSITIONWO2022223714

Non-Patent Literature (NPL) Citations (43) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- A.-K. SOMANI et al., Arch. Dermatol., (20080000), vol. 144, page 1341-
DESCRIPTION- A PSARRASP. EMERYE. M. VITAL, Rheumatol. Oxf. Engl., (20170000), vol. 56, page 1662-
DESCRIPTION- B. BITTNERW. RICHTER, J. Schmidt, Biodrugs, (20180000), vol. 32, page 425-
DESCRIPTION- B. SKAUGS. ASSASSI, Cytokine, (20200000), vol. 132, page 154635-
DESCRIPTION- B. W. HIGGS et al., Ann. Rheum. Dis., (20110000), vol. 70, page 2029-
DESCRIPTION- B. W. HIGGS et al., Ann. Rheum. Dis., (20140000), vol. 73, page 256-
DESCRIPTION- C. GOTAL. CALABRESE, Autoimmunity, (20030000), vol. 36, page 511-
DESCRIPTION- D. A ISENBERG et al., Clin. Exp. Immunol., (19860000), vol. 63, page 450-
DESCRIPTION- E. F. MORAND et al., N. Engl. J. Med., (20200000), vol. 382, page 211-
DESCRIPTION- G. T. FERGUSON et al., J. Asthma Allergy, (20180000), vol. 11, page 63-
DESCRIPTION- J. C. HALLA ROSEN, Nat. Rev. Rheumatol., (20100000), vol. 6, page 40-
DESCRIPTION- J. T. MERRILL et al., Ann. Rheum. Dis., (20160000), vol. 75, page 1909-
DESCRIPTION- J. WENZEL et al., Clin. Exp. Dermatol., (20060000), vol. 31, page 576-
DESCRIPTION- J. WITCHER et al., Br. J. Clin. Pharmacol., (20160000), vol. 81, page 908-
DESCRIPTION- L. BOLKO et al., Brain Pathol. Zurich Switz, (20210000), vol. 31, page e12955-
DESCRIPTION- L. DIETRICHA BRIDGESM. ALBERTINI, Med. Oncol., (20000000), vol. 17, page 64-
DESCRIPTION- M. R. TURNERS. V. BALU-IYER, J. Pharm. Sci., (20180000), vol. 107, page 1247-
DESCRIPTION- R. A FURIE et al., Lancet Rheumatol, (20190000), vol. 1, page e208-
DESCRIPTION- R. FURIE et al., Arthritis Rheumatol. HobokenNj, (20170000), vol. 69, page 376-
DESCRIPTION- R. TUMMALA et al., Lupus Sci. Med., (20180000), vol. 5, page e000252-
DESCRIPTION- S. A GREENBERG et al., Genes Immun, (20120000), vol. 13, page 207-
DESCRIPTION- S. A GREENBERG et al., Neurology, (20050000), vol. 65, page 1782-
DESCRIPTION- X. GUO et al., J. Invest. Dermatol., (20150000), vol. 135, page 2402-
DESCRIPTION- X. LIU et al., Arthritis Rheum, (20130000), vol. 65, page 226-
DESCRIPTION- Y. TANAKAR. TUMMALA, Mod. Rheumatol., (20200000), vol. 0, page 1-
DESCRIPTION- Y. YAO et al., Arthritis Rheum, (20090000), vol. 60, page 1785-
DESCRIPTION- Y. YAO et al., Hum. Genomics Proteomics HGP, (20090000), vol. 2009-
EXAMINATION- VIOLA MARGARIDA ET AL, "Subcutaneous delivery of monoclonal antibodies: How do we get there?", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, (20180802), vol. 286, doi:10.1016/J.JCONREL.2018.08.001, ISSN 0168-3659, pages 301 - 314, XP085478006
OPPOSITION- Anonymous, "Cavg", Wikipedia, (20240429), Wikipedia, URL: https://en.wikipedia.org/wiki/Cavg, XP093191419-
OPPOSITION- D. A. Smith et al., "The use of Cav rather than AUC in safety assessment", Regulatory Toxicology and Pharmacology , (2010), vol. 57, XP027014515-
OPPOSITION- Richard Furie; Munther Khamashta; Joan T. Merrill; Victoria P. Werth; Kenneth Kalunian; Philip Brohawn; Gabor G. Illei; Jorn Drappa; Liangwei Wang; Stephen Yoo, "Anifrolumab, an Anti-Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus", Arthritis & Rheumatology, John Wiley & Sons, Inc., US, US , (20170128), vol. 69, no. 2, doi:10.1002/art.39962, ISSN 2326-5191, pages 376 - 386, XP072275201
OPPOSITION- Beate Bittner et al., "Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities", BioDrugs, (2018), vol. 32, doi:10.1007/s40259-018-0295-0, XP055884493
OPPOSITION- Yu Tian, Enioutina Elena Y., Brunner Hermine I., Vinks Alexander A., Sherwin Catherine M., "Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus", CLINICAL PHARMACOKINETICS., ADIS INTERNATIONAL LTD., AUCKLAND, NZ, NZ , (20170201), vol. 56, no. 2, doi:10.1007/s40262-016-0426-z, ISSN 0312-5963, pages 107 - 125, XP093191416
OPPOSITION- Herbert Struemper et al., "Population Pharmacokinetic and Pharmacodynamic Analysis of Belimumab Administered Subcutaneously in Healthy Volunteers and Patients with Systemic Lupus Erythematosus", Clinical Pharmacokinetics , (2018), vol. 57, doi:10.1007/s40262-017-0586-5, XP055796896
OPPOSITION- Bruce Ian N, Nami Alireza, Schwetje Erik, Pierson M Edward, Rouse Tomas, Chia Yen Lin, Kuruvilla Denison, Abreu Gabriel, Tummala Raj, Lindholm Catharina, "Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study", The Lancet Rheumatology, Elsevier, NL, NL , (20210201), vol. 3, no. 2, doi:10.1016/S2665-9913(20)30342-8, ISSN 2665-9913, pages e101 - e110, XP009556240
OPPOSITION- Morand Eric F., Furie Richard, Tanaka Yoshiya, Bruce Ian N., Askanase Anca D., Richez Christophe, Bae Sang-Cheol, Brohawn Philip Z., Pineda Lilia, Berglind Anna, Tummala Raj, "Trial of Anifrolumab in Active Systemic Lupus Erythematosus", The New England journal of medicine, Massachusetts Medical Society, US, US , (20200116), vol. 382, no. 3, doi:10.1056/NEJMoa1912196, ISSN 0028-4793, pages 211 - 221, XP055836339
OPPOSITION- Tanaka Yoshiya, Takeuchi Tsutomu, Okada Masato, Ishii Tomonori, Nakajima Hiroshi, Kawai Shinichi, Nagashima Takao, Hayashi Nobuya, Wang Liangwei, Tummala Raj, "Safety and tolerability of anifrolumab, a monoclonal antibody targeting type I interferon receptor, in Japanese patients with systemic lupus erythematosus: A multicenter, phase 2, open-label study", Modern Rheumatology, Springer Japan, JP, JP , (20200102), vol. 30, no. 1, doi:10.1080/14397595.2019.1583833, ISSN 1439-7595, pages 101 - 108, XP093191415
OPPOSITION- Tanaka Yoshiya, Tummala Raj, "Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials", Modern Rheumatology, Springer Japan, JP, JP , (20210102), vol. 31, no. 1, doi:10.1080/14397595.2020.1812201, ISSN 1439-7595, pages 1 - 12, XP055935507
OPPOSITION- Raj Tummala et al., "Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers", Lupus Science & Medicine, (2018), vol. 5, doi:10.1136/lupus-2017-000252, XP055935289
OPPOSITION- Tummala Raj, Abreu Gabriel, Pineda Lilia, Michaels M Alex, Kalyani Rubana N, Furie Richard A, Morand Eric F, "Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials", Lupus Science & Medicine, Lupus Foundation of America, BMJ, BMJ , (20210111), vol. 8, no. 1, doi:10.1136/lupus-2020-000464, ISSN 2053-8790, page e000464, XP093191413
OPPOSITION- Avram Goldberg et al., "Dose-escalation of human anti-interferon-a receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study", Arthritis Research & Therapy , (2014), vol. 16, doi:10.1186/ar4492, page R57, XP021184149
OPPOSITION- Varkhede Ninad, Forrest Laird, "Understanding the Monoclonal Antibody Disposition after Subcutaneous Administration using a Minimal Physiologically based Pharmacokinetic Model", JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, CANADIAN SOCIETY FOR PHARMACEUTICAL SCIENCES, EDMONTON, CA, CA , vol. 21, no. 1s, doi:10.18433/jpps30028, ISSN 1482-1826, pages 130s - 148s, XP093191407
OPPOSITION- Felten Renaud, Scher Florence, Sagez Flora, Chasset François, Arnaud Laurent, "Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date", Drug Design, Development and Therapy, (20190119), Volume 13, doi:10.2147/DDDT.S170969, pages 1535 - 1543, XP093015965

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents